ResearcherTel Aviv UniversityActive in the last 2 years
Alex Barenboim
Matched on ORCID iD 0000-0001-7839-9005; OpenAlex author ID A5033584049. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper
Papers 5
- The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuva… Co-author DOI 10.3390/jcm13175206↗
- Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Co-author DOI 10.3390/cancers15113049↗
- Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-020-08469-8↗
- ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy. First author DOI 10.1245/s10434-020-08495-6↗
- Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Co-author DOI 10.1016/j.ejso.2018.07.057↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nir Lubezky · 5 shared papers, 2018–2024 · strength 0.75
- Paper The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreati… DOI 10.3390/jcm13175206↗
- Paper ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Plat… DOI 10.1245/s10434-020-08495-6↗
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049↗
- Joseph M. Klausner · 4 shared papers, 2018–2024 · strength 0.56
- Paper The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreati… DOI 10.3390/jcm13175206↗
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049↗
- Paper Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline … DOI 10.1245/s10434-020-08469-8↗
- Guy Lahat · 3 shared papers, 2018–2023 · strength 0.35
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049↗
- Paper Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline … DOI 10.1245/s10434-020-08469-8↗
- Paper Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. DOI 10.1016/j.ejso.2018.07.057↗
- Ido Wolf · 3 shared papers, 2018–2023 · strength 0.35
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049↗
- Paper Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline … DOI 10.1245/s10434-020-08469-8↗
- Paper Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. DOI 10.1016/j.ejso.2018.07.057↗
- Talia Golan · 2 shared papers, 2020 · strength 0.29
- Paper ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Plat… DOI 10.1245/s10434-020-08495-6↗
- Paper Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline … DOI 10.1245/s10434-020-08469-8↗
- Yossi Maman · 1 shared paper, 2023 · strength 0.18
- Ido Nachmany · 2 shared papers, 2018–2020 · strength 0.17
- Paper Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline … DOI 10.1245/s10434-020-08469-8↗
- Paper Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. DOI 10.1016/j.ejso.2018.07.057↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.